拜玛林制药

最新新闻

• 评级变动
  William Blair Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/19
• 评级变动
  A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $70 to $124
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• 评级变动
  Piper Sandler Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $88
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  Piper Sandler Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $90
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• 评级变动
  Stifel Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating, Maintains Target Price $70
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 评级变动
  Piper Sandler Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $88
  \u5e02\u573a\u8d44\u8baf · 2026/8/26
• Citi Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• 评级变动
  A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $86 to $120
  \u5e02\u573a\u8d44\u8baf · 2026/8/19
• 评级变动
  Barclays Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $105
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• J.P. Morgan Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $86
  \u5e02\u573a\u8d44\u8baf · 2026/9/21
• BMO Capital Upgrades Biomarin Pharmaceutical(BMRN.US) to Buy Rating, Raises Target Price to $97
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• 评级变动
  Cantor Fitzgerald Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $86
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• Guggenheim Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Cuts Target Price to $86
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  TD Cowen Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $120
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• 评级变动
  CCORF Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $114
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• 评级变动
  A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $62 to $124
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• Morgan Stanley Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $124
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• 评级变动
  Wells Fargo Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $80
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• 评级变动
  CCORF Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $114
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  Barclays Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $111
  \u5e02\u573a\u8d44\u8baf · 2026/8/17

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。